<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590082</url>
  </required_header>
  <id_info>
    <org_study_id>2011-1165</org_study_id>
    <secondary_id>NCI-2014-01836</secondary_id>
    <nct_id>NCT01590082</nct_id>
  </id_info>
  <brief_title>Doxycycline, Temozolomide and Ipilimumab in Melanoma</brief_title>
  <official_title>Phase I / II Study of the Combination of Doxycycline With Temozolomide and Ipilimumab in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of doxycycline&#xD;
      that can be combined with temozolomide and ipilimumab in patients with advanced melanoma. The&#xD;
      safety and level of effectiveness of the study drug combination will also be studied.&#xD;
&#xD;
      Doxycycline is designed to treat bacterial infection. It also blocks a protein called iNOS&#xD;
      that is important in tumor cell growth, which may slow the growth of or kill cancer cells.&#xD;
&#xD;
      Temozolomide is designed to stop cancer cells from making new DNA (the genetic material of&#xD;
      cells). This may stop the cancer cells from dividing into new cells.&#xD;
&#xD;
      Ipilimumab is designed to block the activity of cells that decrease the immune system's&#xD;
      ability to fight cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you join this study. Up to 5 groups of 3-6 participants will be enrolled&#xD;
      in the Phase I portion of the study, and up to 28 participants will be enrolled in Phase II.&#xD;
&#xD;
      If you are enrolled in the Phase I portion, the dose of doxycycline you receive will depend&#xD;
      on when you joined this study. The first group of participants will receive the lowest dose&#xD;
      level of doxycycline. Each new group will receive a higher dose of doxycycline than the group&#xD;
      before it, if no intolerable side effects were seen. This will continue until the highest&#xD;
      tolerable dose of doxycycline is found.&#xD;
&#xD;
      If you are enrolled in the Phase II portion, you will receive doxycycline at the highest or&#xD;
      most clinically active dose that was tolerated in the Phase I portion.&#xD;
&#xD;
      All participants will receive the same dose level of temozolomide and ipilimumab.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will start taking doxycycline on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1&#xD;
      starts) by mouth 2 times a day by itself for 1 week. You should fast (not eat or drink&#xD;
      anything but water) for at least 2 hours before and 1 hour after you take the study drug.&#xD;
&#xD;
      After that, on Day 1 of Cycle 1, you will start taking the combination of temozolomide and&#xD;
      ipilimumab. You will receive ipilimumab by vein over 90 minutes every 3 weeks.&#xD;
&#xD;
      On Day 1 of Cycle 1, you will start taking temozolomide by mouth with about 1 cup (8 ounces)&#xD;
      of water on Days 1-4 of each cycle. You should fast for at least 2 hours before and 2 hours&#xD;
      after you take the study drug.&#xD;
&#xD;
      You will continue taking doxycycline by mouth 2 times a day throughout the study.&#xD;
&#xD;
      Each study cycle is 3 weeks except the first cycle, which is 4 weeks. This is because it&#xD;
      includes 1 week of doxycycline given by itself.&#xD;
&#xD;
      You will be given a study drug diary to record the times and doses that you take the study&#xD;
      drugs. You should bring the diary to each study visit. You should also bring any leftover&#xD;
      study drug with you to each study visit.&#xD;
&#xD;
      Study visits:&#xD;
&#xD;
      At every study visit, you will be asked about any drugs you may be taking, how you are&#xD;
      feeling, and if you have had any side effects.&#xD;
&#xD;
      On Day -6 of Cycle 1:&#xD;
&#xD;
        -  You will have a physical exam if not done in the past 8 days.&#xD;
&#xD;
        -  Your weight and vital signs will be measured.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests if this was not done in the&#xD;
           past 8 days.&#xD;
&#xD;
        -  Blood (about 4 tablespoons) will be drawn for biomarker testing. Biomarkers are found in&#xD;
           the blood and tissue and may be related to your reaction to the study drugs.&#xD;
&#xD;
      On Day 1 of Cycles 1 and 2:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 5 tablespoons) will be drawn for routine tests and biomarker testing.&#xD;
&#xD;
        -  You will have an ECG.&#xD;
&#xD;
        -  On Day 1 of Cycle 1, if you are in Phase II of the study, you will have a tumor biopsy&#xD;
           performed to test if doxycycline is able to block the iNOS protein. This biopsy is&#xD;
           optional if you are in Phase I.&#xD;
&#xD;
      On Day 8 of Cycle 1, if you are in Phase I:&#xD;
&#xD;
        -  Blood (about 5 tablespoons) will be drawn for routine tests and biomarker testing.&#xD;
&#xD;
        -  Your vital signs will be measured.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
      On Day 15 of Cycle 1, if you are in Phase I, blood (about 5 tablespoons) will be drawn for&#xD;
      routine tests and biomarker testing.&#xD;
&#xD;
      On Day 1 of Cycles 3 and beyond:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
      Every 6 weeks (2 cycles), you will have a CT scan, an MRI scan, and/or a bone scan to check&#xD;
      the status of the disease.&#xD;
&#xD;
      Length of Treatment:&#xD;
&#xD;
      You may continue taking doxycycline for as long as the doctor thinks it is in your best&#xD;
      interest. You may continue receiving temozolomide and ipilimumab for up to 4 cycles.&#xD;
&#xD;
      You will no longer be able to take the study drugs if the disease gets worse, if you start&#xD;
      having other health problems, if intolerable side effects occur, or if you are unable to&#xD;
      follow study directions.&#xD;
&#xD;
      Your participation on the study will be over once you have completed the end-of-treatment&#xD;
      visit.&#xD;
&#xD;
      End-of-Treatment Visit:&#xD;
&#xD;
      Within 4 weeks after your last dose of study drugs:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your weight and vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 5 tablespoons) will be drawn for routine tests and biomarker testing.&#xD;
&#xD;
        -  You will have an ECG.&#xD;
&#xD;
        -  You will have a tumor biopsy performed to test if there is any change in the level of&#xD;
           iNOS protein.&#xD;
&#xD;
      This is an investigational study. Temozolomide is FDA approved and commercially available to&#xD;
      treat advanced brain tumors. It is commonly used to treat advanced melanoma but is not FDA&#xD;
      approved for it. Ipilimumab is FDA approved and commercially available to treat advanced&#xD;
      melanoma. Doxycycline is FDA approved and commercially available to treat various infections,&#xD;
      but using it to treat cancer is investigational.&#xD;
&#xD;
      Up to 58 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual slow due to alternate trials and treatment options.&#xD;
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Participant Response</measure>
    <time_frame>2 cycles, up to 7 weeks</time_frame>
    <description>Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. Complete Response (CR): Disappearance all target lesions; Any pathological lymph nodes must be &lt;10mm in short axis. Partial Response (PR): &gt;30% decrease in sum of diameters of target lesions, reference baseline sum of diameters (e.g. percent change from baseline). Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for progressive disease. Progressive Disease (PD): &gt;20% increase in sum of diameters of target lesions, reference smallest sum of diameters recorded since treatment started (e.g. percent change from nadir, where nadir defined as smallest sum of diameters recorded since treatment start). In addition, sum must have an absolute increase from nadir of 5mm. Not Applicable (NA): No target lesions at baseline. Not Evaluable (NE): Cannot be classified by 1 of 5 preceding definitions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Doxycycline, Ipilimumab, and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)&#xD;
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.</description>
    <arm_group_label>Doxycycline, Ipilimumab, and Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.</description>
    <arm_group_label>Doxycycline, Ipilimumab, and Temozolomide</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS-734016</other_name>
    <other_name>MDX010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
    <arm_group_label>Doxycycline, Ipilimumab, and Temozolomide</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must be age &gt;/= 18 years.&#xD;
&#xD;
          2. Patients must have histologically or cytologically confirmed diagnosis of malignant&#xD;
             (unresectable Stage III or Stage IV) melanoma, not amenable to resection with curative&#xD;
             intent.&#xD;
&#xD;
          3. Patients must have metastatic melanoma which has &gt;25% of melanoma cells stained&#xD;
             positive for iNOS expression by chemiluminescence immunoassay analyzer&#xD;
             (CLIA)-certified immunohistochemistry assay. However, in phase I portion of the study,&#xD;
             the requirement of &gt;25% of melanoma cells stained positive for iNOS expression does&#xD;
             not apply.&#xD;
&#xD;
          4. Patients must be at least 21 days since surgery, radiation therapy and 6 weeks after&#xD;
             immunotherapy with regimens including vaccines, interferon, IL-2, etc. and fully&#xD;
             recovered from adverse effects of these therapies.&#xD;
&#xD;
          5. Patients must have evaluable disease for response.&#xD;
&#xD;
          6. There is no limit on the number of prior therapies for Phase I portion. For Phase II&#xD;
             portion only, patients may have received less than or equal to 1 prior chemotherapy&#xD;
             regimen for metastatic melanoma. There is no limit on prior immunotherapies or kinase&#xD;
             inhibitors. Patients with prior ipilimumab therapy will be excluded during the phase&#xD;
             II portion.&#xD;
&#xD;
          7. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0&#xD;
             or1.&#xD;
&#xD;
          8. Patient must have adequate liver and renal function as documented by the following&#xD;
             laboratory test results within 14 days prior to starting therapy: • total bilirubin&#xD;
             less than or equal to 1.5 x upper limit of normal (ULN); • AST (SGOT) and ALT (SGPT)&#xD;
             less than or equal to 2.5 X ULN or less than or equal to 5 X ULN if liver metastasis&#xD;
             is present; • serum creatinine less than or equal to 1.2 X ULN&#xD;
&#xD;
          9. Patient must have adequate bone marrow function as documented by the following&#xD;
             laboratory test results within 14 days prior to starting therapy: • platelets greater&#xD;
             than 100,000/mm3; • absolute neutrophil count (ANC) greater than 1500/mm3; •&#xD;
             hemoglobin greater than 9.0 g/dL;&#xD;
&#xD;
         10. Patient must have completed any prior chemotherapy, immunotherapy, radiation therapy,&#xD;
             biological therapy, or other investigational cancer therapy at least 4 weeks prior to&#xD;
             starting the study drug(s) and must have recovered from all acute side effects (to&#xD;
             Common Toxicity Criteria for Adverse Effects (CTCAE) less than Grade 1) prior to&#xD;
             initiation of the study drug(s). Patients who were receiving mitomycin C or&#xD;
             nitrosoureas must be 6 weeks from the last administration of chemotherapy. For a prior&#xD;
             BRAF inhibitor, the washout period is 7 days.&#xD;
&#xD;
         11. Patient (man or woman) must agree to practice effective contraception during the&#xD;
             entire study period, unless documentation of infertility exists, and for at least 4&#xD;
             weeks after the last dose of the study drug(s).&#xD;
&#xD;
         12. Patient must be willing and able to sign the informed consent form.&#xD;
&#xD;
         13. Patient must be willing and able to self-administer orally and document all doses of&#xD;
             doxycycline ingested.&#xD;
&#xD;
         14. Patients must be willing to have iNOS expression assay test done on disease easily&#xD;
             amenable to biopsy or suitable tissue obtained within the last 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received doxycycline or other tetracycline-analogs within the 4&#xD;
             weeks prior to the first dose of the study drug.&#xD;
&#xD;
          2. For Phase II portion only, patients with a diagnosis of ocular melanoma will be&#xD;
             excluded.&#xD;
&#xD;
          3. Patients with an inability to swallow tablets or capsules.&#xD;
&#xD;
          4. Patients with a symptomatic malabsorptive disorder (eg, Crohn's Disease) or removal of&#xD;
             either the terminal ileus or more than 2/3 of the small intestine.&#xD;
&#xD;
          5. Patients with active brain metastases or primary central nervous system (CNS)&#xD;
             malignancies; patients with previously treated brain metastasis may be included,&#xD;
             provided that no requirement for steroids and no evidence of progression for greater&#xD;
             than or equal to 8 weeks after a local brain treatment.&#xD;
&#xD;
          6. Patients with an active second malignancy.&#xD;
&#xD;
          7. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          8. Patients with clinically significant illnesses which could compromise participation in&#xD;
             the study, including, but not limited to:uncontrolled diabetes;active or uncontrolled&#xD;
             infection; acute or chronic liver disease (i.e., hepatitis, cirrhosis);confirmed&#xD;
             diagnosis of HIV infection; or, uncontrolled hypertension, symptomatic congestive&#xD;
             heart failure, unstable angina pectoris, myocardial infarction within the past 6&#xD;
             months, or uncontrolled cardiac arrhythmia.&#xD;
&#xD;
          9. Patients with history of autoimmune disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sapna P. Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Advanced melanoma</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Yervoy</keyword>
  <keyword>MDX010</keyword>
  <keyword>BMS-734016</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Temodar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: November 6, 2012 to March 30, 2015. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Doxycycline + Ipilimumab + Temozolomide</title>
          <description>Oral Doxycycline starting dose 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Phase II</title>
          <description>Oral Doxycycline 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: Doxycycline + Ipilimumab + Temozolomide</title>
          <description>Oral Doxycycline starting dose 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
        </group>
        <group group_id="B2">
          <title>Phase II</title>
          <description>Oral Doxycycline 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="53" upper_limit="75"/>
                    <measurement group_id="B2" value="84" lower_limit="84" upper_limit="84"/>
                    <measurement group_id="B3" value="67" lower_limit="53" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Participant Response</title>
        <description>Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. Complete Response (CR): Disappearance all target lesions; Any pathological lymph nodes must be &lt;10mm in short axis. Partial Response (PR): &gt;30% decrease in sum of diameters of target lesions, reference baseline sum of diameters (e.g. percent change from baseline). Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for progressive disease. Progressive Disease (PD): &gt;20% increase in sum of diameters of target lesions, reference smallest sum of diameters recorded since treatment started (e.g. percent change from nadir, where nadir defined as smallest sum of diameters recorded since treatment start). In addition, sum must have an absolute increase from nadir of 5mm. Not Applicable (NA): No target lesions at baseline. Not Evaluable (NE): Cannot be classified by 1 of 5 preceding definitions.</description>
        <time_frame>2 cycles, up to 7 weeks</time_frame>
        <population>Due to early termination participants did not move to Phase 2 and no data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Doxycycline, Ipilimumab, and Temozolomide</title>
            <description>Oral Doxycycline starting dose 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Phase II</title>
            <description>Oral Doxycycline 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Participant Response</title>
          <description>Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. Complete Response (CR): Disappearance all target lesions; Any pathological lymph nodes must be &lt;10mm in short axis. Partial Response (PR): &gt;30% decrease in sum of diameters of target lesions, reference baseline sum of diameters (e.g. percent change from baseline). Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for progressive disease. Progressive Disease (PD): &gt;20% increase in sum of diameters of target lesions, reference smallest sum of diameters recorded since treatment started (e.g. percent change from nadir, where nadir defined as smallest sum of diameters recorded since treatment start). In addition, sum must have an absolute increase from nadir of 5mm. Not Applicable (NA): No target lesions at baseline. Not Evaluable (NE): Cannot be classified by 1 of 5 preceding definitions.</description>
          <population>Due to early termination participants did not move to Phase 2 and no data collected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event evaluation Phase I: Patients will be evaluated at baseline (and/or day -6) and on days 1, 8 and 15 during cycle 1, and then on day 1 every cycle. Phase II: Patients will be evaluated ate baseline (and/or day -6) and on day 1 during cycle 1, and then on day 1 every cycle. Collection up to Cycle 5, approximately 15 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Doxycycline + Ipilimumab + Temozolomide</title>
          <description>Oral Doxycycline starting dose 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Phase II</title>
          <description>Oral Doxycycline 200 mg twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts), thereafter with Ipilimumab 3 mg by vein (IV) on Day 1 of each 21 day cycle for 4 cycles, oral Temozolomide 200 mg/m2 on Days 1 - 4 of each 21 day cycle for 4 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders - (Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - (Other)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Investigations - (Other)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sleep apnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - (Other)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sapna P. Patel, Associate Professor, Melanoma Medical Oncology</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>(713) 792-2921</phone>
      <email>sppatel@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

